Post-transplantation lymphoproliferative disorders in adults
D Dierickx, TM Habermann - New England Journal of Medicine, 2018 - Mass Medical Soc
Post-Transplantation Lymphoproliferative Disorders Solid-organ and hematopoietic stem-
cell transplants are widely used for various life-threatening medical disorders. Prophylaxis …
cell transplants are widely used for various life-threatening medical disorders. Prophylaxis …
[HTML][HTML] Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action
MD Pescovitz - American journal of transplantation, 2006 - Elsevier
Rituximab, chimeric anti-human CD20, is approved for treatment of B-cell lymphoma in
adults. It is being used experimentally in other various immune-related diseases such as …
adults. It is being used experimentally in other various immune-related diseases such as …
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international …
R Trappe, S Oertel, V Leblond, P Mollee… - The lancet …, 2012 - thelancet.com
Background Post-transplantation lymphoproliferative disorder (PTLD) develops in 1–10% of
transplant recipients and can be Epstein–Barr virus (EBV) associated. To improve long-term …
transplant recipients and can be Epstein–Barr virus (EBV) associated. To improve long-term …
Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R …
RU Trappe, D Dierickx, H Zimmermann… - Journal of Clinical …, 2017 - ascopubs.org
Purpose The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative
Disorder (PTLD-1) trial (ClinicalTrials. gov identifier, NCT01458548) established sequential …
Disorder (PTLD-1) trial (ClinicalTrials. gov identifier, NCT01458548) established sequential …
[HTML][HTML] Epstein–Barr virus infection and posttransplant lymphoproliferative disorder
M Green, MG Michaels - American Journal of Transplantation, 2013 - Elsevier
Epstein–Barr virus (EBV) is an important pathogen in recipients of solid organ transplants
(SOT). Infection with EBV manifests as a spectrum of diseases/malignancies ranging from …
(SOT). Infection with EBV manifests as a spectrum of diseases/malignancies ranging from …
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern …
Purpose Adult post-transplantation lymphoproliferative disease (PTLD) has a reported 3-
year overall survival (OS) of 35% to 40%. The impact of rituximab on the outcome of PTLD is …
year overall survival (OS) of 35% to 40%. The impact of rituximab on the outcome of PTLD is …
How I treat EBV lymphoproliferation
HE Heslop - Blood, The Journal of the American Society of …, 2009 - ashpublications.org
Abstract Epstein-Barr virus (EBV)–associated B-cell lymphoproliferation is a life-threatening
complication after hematopoietic stem cell or solid organ transplantation resulting from …
complication after hematopoietic stem cell or solid organ transplantation resulting from …
Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from …
R Al Hamed, AH Bazarbachi, M Mohty - Bone marrow transplantation, 2020 - nature.com
Epstein-Barr virus (EBV) is a ubiquitous herpes virus that infects the majority of the
population worldwide. The virus can establish a lifelong latent infection in host B …
population worldwide. The virus can establish a lifelong latent infection in host B …
[HTML][HTML] The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder
MR Luskin, DS Heil, KS Tan, S Choi… - American Journal of …, 2015 - Elsevier
We examined the associations of Epstein–Barr virus (EBV) status with characteristics and
outcomes of posttransplantation lymphoproliferative disorder (PTLD) by studying 176 adult …
outcomes of posttransplantation lymphoproliferative disorder (PTLD) by studying 176 adult …
[HTML][HTML] Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder★
R Reshef, S Vardhanabhuti, MR Luskin… - American Journal of …, 2011 - Elsevier
Reduction of immunosuppression (RI) is commonly used to treat posttransplant
lymphoproliferative disorder (PTLD) in solid organ transplant recipients. We investigated the …
lymphoproliferative disorder (PTLD) in solid organ transplant recipients. We investigated the …